34597298|PMC8486115
{'Chemical', 'Disease', 'Species', 'CellLine', 'Gene'}
Background
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to spread rapidly throughout the world, with over 174 million confirmed cases and over 3.7 million deaths globally as of June 11, 2021. Seroconversion rates were also higher for younger participants (79% and 93% for 5-mug first doses and 25-mug first doses, respectively, and 43% and 75% for older participants by dose, respectively).For participants administered active vaccine for both doses (Group B:2 doses of 5-mug NVX-CoV2373 and Group D:2 doses of 25-mug NVX-CoV2373), there was a large increase in anti-spike protein binding IgG GMTs at Day 35 following the second dose relative to post-first-dose immune responses, and, again, responses were higher in younger participants relative to older participants. b)line 206 - do you mean' For vaccine participants who received placebo as the second injection, frequencies of solicited local adverse events were similar to participants who received a single dose of placebo'?